Publications by authors named "P Saddier"
Article Synopsis
- This study analyzed the long-term effectiveness of the live zoster vaccine over more than 10 years after vaccination among a large population aged 50 and older in Northern California.
- It used real-world data from electronic health records to assess the vaccine's effectiveness in preventing herpes zoster and related complications, revealing that effectiveness decreased significantly over time.
- For example, vaccine effectiveness dropped from 67% in the first year to only 15% after 10 years for preventing herpes zoster, with similar declines noted for other complications such as postherpetic neuralgia.
Background: The potential for vaccines to induce autoimmunity has been the subject of considerable investigation and autoimmune induction remains a common focus for vaccine safety research. This study assessed the risk of new onset autoimmune conditions among males receiving the 4-valent human papillomavirus (HPV) vaccine (4vHPV).
Methods: Within a US health insurance claims database, we formed a cohort of male 4vHPV vaccine recipients between 2009 and 2016, along with a propensity score matched cohort of males who did not receive the 4vHPV vaccine.
Article Synopsis
- A multiyear study assessed the safety of the nine-valent human papillomavirus vaccine (HPV9, Gardasil®9) after its December 2014 licensure in the USA, comparing emergency department visits and hospitalizations soon after vaccination against control periods.
- The study included over 215,000 individuals, mostly aged 12-13, with findings showing a slight increase in certain health events, but most were attributable to other causes or preexisting conditions.
- No new safety concerns were identified, and all reported deaths during the study were unrelated to the HPV9 vaccine, confirming its overall safety profile.
The 4-valent human papillomavirus (HPV) vaccine (4vHPV vaccine), Gardasil®, is indicated for the prevention of several HPV-related diseases. The objective was to assess the safety of 4vHPV vaccine administered to males as part of routine care. The study used a US health insurance claims database, and included males, age 9 to 26 years, who initiated 4vHPV between October 2009 and December 2016.
View Article and Find Full Text PDFArticle Synopsis
- - The study examines the administration patterns of the quadrivalent HPV vaccine (4vHPV) among US males aged 9 to 26 before a regimen modification in 2016, utilizing health insurance claims data from 2012 to 2016.
- - Out of over 100,000 males who started the vaccine series, only half received the second dose and about a quarter completed the third dose, with many taking a full year between doses instead of the recommended 6 months.
- - The findings indicate that males aged 18 to 21 and those in Western or rural areas were less likely to complete the vaccine series, highlighting the need for improved strategies to increase HPV vaccination rates in this demographic.